BC Extra | Mar 20, 2015
Company News

Management tracks

Cell therapy company Fibrocell Science Inc. (NASDAQ:FCSC) hired Keith Goldan as SVP and CFO. Goldan was SVP and CFO of NuPathe Inc. , which was acquired by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA). Ophthalmic play Neurotech Pharmaceuticals...
BC Week In Review | Oct 13, 2014
Company News

Zynerba management update

Zynerba Pharmaceuticals Inc. , Radnor Pa.   Business: Neurology, Autoimmune, Drug delivery   Hired: Armando Anido as CEO and chairman, formerly CEO of NuPathe Inc. , which Teva Pharmaceutical Industries Ltd acquired; and Terri Sebree as president,...
BC Week In Review | Jul 28, 2014
Company News

AgeneBio management update

AgeneBio Inc. , Carmel, Ind.   Business: Neurology   Hired: Jerry McLaughlin as president and CEO, formerly SVP and chief commercial officer of NuPathe Inc. , which Teva Pharmaceutical Industries Ltd. acquired  ...
BC Week In Review | Jun 9, 2014
Company News

Labrys Biologics Inc., Teva deal

Teva will acquire Labrys for $200 million in cash up front plus up to $625 million in developmental milestones. Labrys' sole compound is LBR-101 , which is in Phase IIb testing to treat and prevent chronic...
BioCentury | Jun 9, 2014
Finance

Liberating Labrys

Less than two years after pumping $31 million into migraine play Labrys Biologics Inc. , investors will see a front-loaded return in a takeout by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA). Teva is acquiring Labrys for $200...
BC Extra | Jun 3, 2014
Top Story

Teva to acquire migraine play Labrys

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will acquire Labrys Biologics Inc. (San Mateo, Calif.) for $200 million in cash up front plus up to $625 million in developmental milestones. Labrys' sole compound is LBR-101 , which is...
BC Week In Review | Mar 3, 2014
Company News

Immunome board of directors update

Immunome Inc. , Wynnewood, Pa.   Business: Infectious, Antibodies   Hired: Jane Hollingsworth as executive chair, formerly CEO of NuPathe Inc. , which Teva Pharmaceutical Industries Ltd. acquired  ...
BC Week In Review | Feb 24, 2014
Company News

NuPathe, Teva deal

Teva completed its acquisition of specialty pharma NuPathe for $3.65 per share in cash up front, or about $144 million. NuPathe shareholders are eligible to receive up to an additional $3.15 per share tied to...
BC Week In Review | Jan 27, 2014
Company News

Endo, NuPathe, Teva deal

Specialty pharma NuPathe terminated a merger with Endo and instead will now be acquired by Teva. Teva is paying $3.65 per NuPathe share in cash up front, or about $144 million. The price is a...
BioCentury | Jan 27, 2014
Finance

Teva blinks again

Teva blinks again Three months after President and CEO Jeremy Levin's ouster from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) shocked and disappointed investors, Chairman Phillip Frost appears to be extending an olive branch. In a letter...
Items per page:
1 - 10 of 83
BC Extra | Mar 20, 2015
Company News

Management tracks

Cell therapy company Fibrocell Science Inc. (NASDAQ:FCSC) hired Keith Goldan as SVP and CFO. Goldan was SVP and CFO of NuPathe Inc. , which was acquired by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA). Ophthalmic play Neurotech Pharmaceuticals...
BC Week In Review | Oct 13, 2014
Company News

Zynerba management update

Zynerba Pharmaceuticals Inc. , Radnor Pa.   Business: Neurology, Autoimmune, Drug delivery   Hired: Armando Anido as CEO and chairman, formerly CEO of NuPathe Inc. , which Teva Pharmaceutical Industries Ltd acquired; and Terri Sebree as president,...
BC Week In Review | Jul 28, 2014
Company News

AgeneBio management update

AgeneBio Inc. , Carmel, Ind.   Business: Neurology   Hired: Jerry McLaughlin as president and CEO, formerly SVP and chief commercial officer of NuPathe Inc. , which Teva Pharmaceutical Industries Ltd. acquired  ...
BC Week In Review | Jun 9, 2014
Company News

Labrys Biologics Inc., Teva deal

Teva will acquire Labrys for $200 million in cash up front plus up to $625 million in developmental milestones. Labrys' sole compound is LBR-101 , which is in Phase IIb testing to treat and prevent chronic...
BioCentury | Jun 9, 2014
Finance

Liberating Labrys

Less than two years after pumping $31 million into migraine play Labrys Biologics Inc. , investors will see a front-loaded return in a takeout by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA). Teva is acquiring Labrys for $200...
BC Extra | Jun 3, 2014
Top Story

Teva to acquire migraine play Labrys

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will acquire Labrys Biologics Inc. (San Mateo, Calif.) for $200 million in cash up front plus up to $625 million in developmental milestones. Labrys' sole compound is LBR-101 , which is...
BC Week In Review | Mar 3, 2014
Company News

Immunome board of directors update

Immunome Inc. , Wynnewood, Pa.   Business: Infectious, Antibodies   Hired: Jane Hollingsworth as executive chair, formerly CEO of NuPathe Inc. , which Teva Pharmaceutical Industries Ltd. acquired  ...
BC Week In Review | Feb 24, 2014
Company News

NuPathe, Teva deal

Teva completed its acquisition of specialty pharma NuPathe for $3.65 per share in cash up front, or about $144 million. NuPathe shareholders are eligible to receive up to an additional $3.15 per share tied to...
BC Week In Review | Jan 27, 2014
Company News

Endo, NuPathe, Teva deal

Specialty pharma NuPathe terminated a merger with Endo and instead will now be acquired by Teva. Teva is paying $3.65 per NuPathe share in cash up front, or about $144 million. The price is a...
BioCentury | Jan 27, 2014
Finance

Teva blinks again

Teva blinks again Three months after President and CEO Jeremy Levin's ouster from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) shocked and disappointed investors, Chairman Phillip Frost appears to be extending an olive branch. In a letter...
Items per page:
1 - 10 of 83